REG - Integrated Diag Hdgs - IDH appoints Group CFO, VP and Board Member

Integrated Diagnostics HoldingsAnnouncement

18/01/2024 16:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240118:nRSR2011Aa&default-theme=true

RNS Number : 2011A  Integrated Diagnostics Holdings PLC  18 January 2024

IDH appoints Group CFO, VP and Board Member

18 January 2024

(Cairo and London) - Integrated Diagnostics Holdings ("IDH," "the Group," or
"the Company"), a leading consumer clinical laboratory, and one of the largest
diagnostic players in the Middle East and Africa, with operations in Egypt,
Jordan, Nigeria, Sudan, and Saudi Arabia, announces the appointment of Sherif
El Zeiny as Board Member, Vice President and Group Chief Financial Officer,
effective 18 January 2024. El Zeiny is a seasoned and certified Board Director
and Executive Partner, boasting over three decades of experience in financial
management, business leadership, and corporate strategy. Previously, El Zeiny
served as Vice President and Group Chief Financial Officer at Elsewedy
Electric.

Commenting on El Zeiny's appointment, Dr. Hend El Sherbini, Group Chief
Executive Officer, said: "On behalf of IDH's Board of Directors and management
team, I am excited to welcome Sherif on board as Board Member, VP and Group
CFO. Along with the entire IDH team, I will prioritize ensuring a smooth and
efficient transition as Sherif fills his role and the Group focuses on
expanding our operations, growing our top-line, and improving our margins
across our geographies. I am confident that the extensive experience and
unique skill set that Sherif brings with him will prove vital to our continued
financial success moving forward."

Sherif El Zeiny, Group Chief Financial Officer, added: "I am thrilled to join
IDH in such a pivotal time in its history. I am particularly excited about the
Company's new venture into Saudi Arabia, which will inevitably serve to widen
its patient base and cement its position as a regional leader in the
diagnostics field. With a firm belief that financial growth is the bedrock of
any successful business, I look forward to optimizing our resources, making
smart investments, and driving responsible growth under the umbrella of strong
corporate governance and digital transformation to usher in another era of
success for IDH and its shareholders."

 

-Ends-

 

 

About Integrated Diagnostics Holdings (IDH)

IDH is a leading diagnostics services provider in the Middle East and Africa
offering a broad range of pathology and radiology tests to patients in Egypt,
Jordan, Nigeria, Sudan, and soon launching in Saudi Arabia. The Group's core
brands include Al Borg, Al Borg Scan and Al Mokhtabar in Egypt, as well as
Biolab (Jordan), Ultralab and Al Mokhtabar Sudan (both in Sudan) and Echo-Lab
(Nigeria). A long track record for quality and safety has earned the Company a
trusted reputation, as well as internationally recognised accreditations for
its portfolio of over 3,000 diagnostics tests. From its base of 552 branches
as of 31 December 2022, IDH served over 8.7 million patients and performs more
than 32.7 million tests in 2022. IDH will continue to add laboratories through
a Hub, Spoke and Spike business model that provides a scalable platform for
efficient expansion. Beyond organic growth, the Group's expansion plans
include acquisitions in new Middle Eastern, African, and East Asian markets
where its model is well-suited to capitalise on similar healthcare and
consumer trends and capture a significant share of fragmented markets. IDH has
been a Jersey-registered entity with a Standard Listing on the Main Market of
the London Stock Exchange (ticker: IDHC) since May 2015 with a secondary
listing on the EGX since May 2021 (ticker: IDHC.CA).

Learn more at idhcorp.com (http://idhcorp.com) .

 

Contact

Tarek Yehia

Investor Relations Director

T: +20 (0)2 3332 1126 | M: +20 10 6882 6678 | tarek.yehia@idhcorp.com
(mailto:tarek.yehia@idhcorp.com)

 

LEI: 2138007JN9NUWKKTS790

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOASFFFMAELSESF